Clinical research by Dana-Farber scientists suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could ...

Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent ...

Q4 2024 Earnings Call Transcript February 18, 2025 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.04, ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $22.0, along with a high estimate of $25.00 and a low estimate of $14.00. Highlighting a ...

"Once in your life, we should try." Peter Lau's simple seven-word mantra has guided the world's most accomplished racehorse ...

The global lung cancer surgery market is poised for transformative growth from 2025 to 2035, driven by the increasing ...

Australia’s best 2000m horses – headed by multiple G1 winners Mr Brightside and Alligator Blood – had to give best as ...

Introduction Mental health issues among women in Sub-Saharan Africa (SSA), especially those living with HIV, pose a major public health challenge. Despite the established connections between HIV ...

Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...

Clinical research suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could increase efficacy.

Scientists have developed a breakthrough method to track diet using stool metagenomic data. This non-invasive, data-driven approach offers an objective alternative to traditional food diaries and ...